On March 25, 2019 Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA,NASDAQ: KZIA) reported that it has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2019 Annual Meeting (Press release, Kazia Therapeutics, MAR 25, 2019, View Source [SID1234534572]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AACR’s Annual Meeting is one of the top-tier academic conferences worldwide and brings together around 20,000 representatives from academia, industry, government and advocacy organisations from across the globe. The meeting is being held from 29 March to 3 April at the Georgia World Congress Center in Atlanta, Georgia, USA.
Clinical Program Director, Daniel Berg will be presenting on Kazia’s Cantrixil Phase I in ovarian cancer at the event on 1 April 2019. Mr Berg will present data from Part A of the study — the dose escalation component — which completed recruitment in October 2018.
TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer. It was developed in Australia and initial preclinical studies were conducted at Yale University. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.
The abstract presentation is entitled: Phase I Study of Intraperitoneal TRX-E-002-1 in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer: Results of Dose-Escalation Phase.
The abstract has been authored by the trial’s Principal Investigators (PIs) – led by the two primary PIs in Australia and the US: Associate Professor Jermaine Coward at the ICON Cancer Care in Brisbane, Queensland and Dr Don Dizon at the Lifespan Cancer Institute at Rhode Island Hospital. The trial is being conducted across six sites in the US and Australia as follows:
Country
State
Site
Principal Investigator
US
Rhode Island
Lifespan Cancer Institute, Providence
Dr. Don Dizon
US
Oklahoma
Stephenson Cancer Center, Oklahoma City
Assoc. Prof. Kathleen Moore
US
Texas
Mary Crowley Cancer Research Centre, Dallas
Dr. Minal Barve
Australia
Queensland
ICON Cancer Care, Brisbane
Assoc. Prof. Jermaine Coward
Australia
New South Wales
Westmead Hospital, Sydney
Prof. Paul Harnett
Australia
South Australia
Flinders Medical Centre, Adelaide
Dr. Ganessan Kichenadasse
"The key objective with Part A of the Phase I study was to assess the safety of the drug and find the right dose level to take the study to the next stage. We are delighted to be presenting our data at the AACR (Free AACR Whitepaper) meeting and we look forward to discussing our findings with clinicians and potential partners," said Cantrixil Program Director Daniel Berg.
The presentation session details are as follows:
Session Title: Phase I Clinical Trials: Part 3
Date and Time: Monday April 1, 2019 1:00 PM – 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 16
Poster Board Number: 15
Permanent Abstract Number: CT091
Interested parties are encouraged to attend and can add the session to their itinerary here: View Source!/6812/session/1315
Meanwhile, the link to the abstract is here: View Source!/6812/presentation/9899
The content of the abstract and presentation is embargoed until the start of the conference when it will be available through the above link and on the Kazia website.